Trial Information

Summary: A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) versus Placebo in Combination with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)

The ROSE Rheumatoid Arthritis Study is being conducted in people diagnosed with moderate to severe active RA. It is designed to demonstrate the response of the study drug in combination with Methotrexate on RA.

Patient Inclusion Criteria:

• Male or female 18 or older,
• Diagnosis of active RA > 6 months,
• Receiving treatment on an outpatient basis,
• Taking stable dose of Methotrexate > 12 weeks
• (other criteria apply)

Patient Exclusion Criteria:

• Major surgery within 8 weeks,
• Rheumatic autoimmune disease other than RA,
• Prior history of or current inflammatory disease other than RA.
• History of diverticulitis,
• (Other criteria apply)

If you would like to learn more about participating in this study, please send an e-mail message using the form below.